The increasing prevalence of chronic diseases, rising healthcare expenditures, and the rapid adoption of technological innovations transforming different aspects of drug discovery, development, and distribution are expected to position the pharmaceutical industry for continued growth and expansion.
Given this backdrop, it could be wise to consider fundamentally strong pharma stocks Collegium Pharmaceutical, Inc. (COLL), Green Thumb Industries Inc. (GTBIF), and Bristol-Myers Squibb Company (BMY), primed for investment opportunities this month.
